JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - H.C. Wainwright has reiterated its Buy rating for BiomX (NYSE:PHGE) with a price target of $15.00, according to a research note released Tuesday. The target represents significant upside potential from the current price of $0.43, with analysts’ consensus targets ranging between $15-16.
The research firm’s analysis focuses on BiomX’s two lead phage cocktail assets targeting cystic fibrosis infections and diabetic foot osteomyelitis (DFO), which contribute 52% and 48% respectively to their valuation model.
H.C. Wainwright’s valuation assumes BiomX will secure an ex-U.S. partner with a 23% royalty arrangement for both assets, using a clinical net present value model that incorporates various commercial profile assumptions.
The firm identified several factors that could drive upside potential, including higher market penetration, additional indications, expanded ex-U.S. opportunities, and improved chances of success based on clinical progress.
Potential risks to achieving the price target include failed or inconclusive clinical trials, funding challenges, dilutive capital raises, and lack of commercial success, according to the research note. The company’s next earnings report is scheduled for August 12, 2025. Get deeper insights into BiomX’s valuation metrics and 12 additional key ProTips with a subscription to InvestingPro.
In other recent news, BiomX Inc. has initiated patient dosing in its Phase 2b trial for BX004, a phage therapy targeting antibiotic-resistant Pseudomonas aeruginosa infections in cystic fibrosis patients. The study, which is randomized, double-blind, and placebo-controlled, will involve approximately 60 patients receiving treatment via inhalation over an 8-week period. BiomX has secured Fast Track and Orphan Drug designations from the FDA for BX004 and expects topline results in the first quarter of 2026. The trial will assess various efficacy endpoints, including bacterial burden reduction and improvements in lung function and quality of life. Additionally, H.C. Wainwright analyst Joseph Pantginis has adjusted the price target for BiomX, reducing it to $15 from $21, while maintaining a Buy rating. This follows BiomX’s announcement of its first-quarter financial results for 2025, which showed a loss per share of $0.33, better than the anticipated $0.42 loss per share. The company concluded the quarter with $21.2 million in cash reserves, expected to fund operations into early 2026. BiomX is also engaged in discussions with the FDA about real-world evidence data to support potential future filings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.